Billings Clinic
Especially For:

Clinical Trials

Title   Melanoma E1609
Description   E1609 A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a- 2b for Resected High-Risk Melanoma
IRB Number   E1609
Category   Melanoma
Inclusion/Notes   must have been surgically rendered free of disease with negative margins
Status   Active
Start Date   05/21/2012
Principal Investigator (PI)   Brock Whittenberger, MD
Contact Name   Judy Miller RN
Contact Email   jmilller4@billingsclinic.org
Phone   (406) 435-7482
Funding Source   NCI
Print This Page
Email to a Friend
Home | Contact | Site Map | Site Privacy Policy | Terms & Conditions | Patient Privacy Policy | Medical Records | Fast Command
2800 10th Ave. North | P.O. Box 37000 | Billings, Montana 59107 | 406.238.2500
© Copyright 2014 Billings Clinic. All Rights Reserved.